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to a population vulnerable to VPDs in the 
United States.
Finally, in Mr. Trump’s vision of 
“America first,” economic aspects tend to 
be prioritized, and global challenges such 
as climate change tend to be neglected. 
However, Mr. Trump’s doubts about cli-
mate change [8] must be discussed from 
a scholarly point of view because if coun-
termeasures to control climate change are 
not taken, mosquito-borne diseases may 
be left untreated. As a fact, we should take 
note that since 2015, 220 cases of locally 
acquired mosquito-borne Zika infec-
tion have been reported in some parts of 
Florida and Texas [9]. We believe that any 
policies and orders should be announced 
after the due deliberation of several 
aspects including the scientific facts.
Our challenge is to control possible 
outbreaks of infectious diseases, and Mr. 
Trump’s challenge is to protect his coun-
try and the children of the United States 
from the view of a “globalized world.” 
We believe that not only the guarantee of 
vaccine service to all children irrespective 
of their nationality, ethnicity, or race but 
also addressing climate change honestly 
will create a stronger wall than any that 
might be built at a border.
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C O R R E S P O N D E N C E
Artemether-Lumefantrine 
Treatment Failure in 
Nonimmune European Travelers 
With Plasmodium falcipar-
um Malaria: Do We Need to 
Reconsider Dosing in Patients 
From Nonendemic Regions?
We read with interest the recent article 
by Sóden and colleagues [1], which de-
scribes 310 imported Plasmodium fal-
ciparum malaria cases in Sweden treat-
ed with oral regimens: 95 of 310 with 
artemether-lumefantrine (AL), 162 of 
310 with mefloquine, 36 of 310 with 
atovaquone-proguanil, and 17 of 310 with 
other regimens. Among patients treated 
with AL, a high rate of late treatment fail-
ures was observed: 5.3% (5/95) of patients 
showed recrudescence of P. falciparum 
20–28 days after completion of treat-
ment, whereas no late treatment failures 
were seen in patients treated with other 
oral regimens. While genotyping did not 
reveal any evidence of underlying drug 
resistance, pharmacokinetic data suggest 
that the observed treatment failures may 
be attributable to subtherapeutic lume-
fantrine plasma concentrations [1].
As the area under the curve of plasma 
lumefantrine concentration vs time is the 
main determinant for eradication of resid-
ual parasites not cleared by artemether, and 
thus the determinant of clinical efficacy 
[2–4], this explanation appears plausible.
Sóden and colleagues also provide 
a review of published reports on AL 
treatment, which includes the only pro-
spective study on the efficacy of AL 
including nonimmune European travel-
ers published in 2008 [5]. In this study, 
165 nonimmune patients from Europe 
and nonmalarious regions of Colombia 
with uncomplicated falciparum malaria 
were treated with the standard 6-dose 
AL regimen. We would like to highlight 
that, although the cited overall failure 
rate of AL treatment in this study was 
3.6% (6/165), the failure rate in the sub-
group analysis of European travelers (not 
shown) was 5.3% (3/57), and thus identi-
cal to the rate now reported by Sóden and 
colleagues in Swedish patients.
Considering that (i) the currently used 
6-dose regimen of AL was a consequence 
of the unacceptably high recrudescence 
rates following the initially recom-
mended 4-dose regimen of AL [6, 7], that 
(ii) nonimmune patients lacking acquired 
partial immunity have a higher risk of 
treatment failure compared with patients 
from endemic regions [3], that (iii) at the 
time of AL registration, almost no data 
from nonimmune patients were available, 
that (iv) the observed treatment failures 
with AL are very likely attributable to low 
lumefantrine plasma levels, and that (v) 
the now reconfirmed failure rate of 5.3% 
in nonimmune patients challenges the 
current treatment strategy, reconsidera-
tion of the dosing strategy of AL in this 
patient population is warranted.
To achieve sufficiently high lumefantrine 
plasma levels over time, either the extension 
of the current 3-day AL regimen to a 5-day 
“augmented regimen” [3] or the spreading 
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of the 6-dose regimen from currently 3 days 
(0, 8, 24, 36, 48, 60 hours) to 5 days (0, 8, 24, 
48, 72, 96 hours) may be discussed [8]. The 
question of whether a higher cumulative 
dose of lumefantrine in an augmented reg-
imen may increase the rate of gastrointesti-
nal side effects (primarily vomiting [3]) will 
be answered once the results of the “AL3vs5” 
study, comparing the 3-day AL regimen 
with a 5-day regimen, are published [9].
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